利福昔明治疗炎症性肠病的研究进展  

Research progress of rifaximin in the treatment of inflammatory bowel disease

作　　者：吴书妹[1] 郭传勇[1] 

机构地区：[1]上海市第十人民医院消化内科,上海200072

出　　处：《胃肠病学和肝病学杂志》2013年第5期492-494,共3页Chinese Journal of Gastroenterology and Hepatology

基　　金：国家自然科学基金(81101579);上海市科委创新行动计划国际合作课题(11430702400);上海市卫生局课题(2011287)

摘　　要：炎症性肠病(IBD)的病因和发病机制尚未完全明确。研究认为肠道黏膜免疫系统异常反应所导致的炎症反应起重要作用。肠道菌群在促进及维持IBD的炎症反应中起重要作用。因此,抗生素可用于治疗IBD。利福昔明(rifaximin)是一种用于局部肠道感染的药物。已有越来越多的临床及基础研究显示,无论利福昔明单用还是联合其他药物治疗IBD,都取得较好的疗效。因此,本文就利福昔明治疗IBD的安全性及有效性作一综述。The etiology and pathogenesis of inflammatory bowel disease （IBD） are unknown. Researches suggest that intestinal mucosal inflammation caused by abnormal immune system response plays an important role in IBD. The gut mi- crobiota plays a role in promoting and maintaining inflammation, hence the antibiotics can be used in the treatment of those disorders. Rifaximin is a kind of drugs to local intestinal infection. An increasing number of both clinical and labo- ratory-derived observations support the good efficacy of rifaximin either alone or in combination with other agents for the treatment of IBD. This paper summarized the efficacy and safety of rifaximin in treatment for IBD.

关 键 词：炎症性肠病 利福昔明 治疗 

分 类 号：R574[医药卫生—消化系统]